Search results
Results from the WOW.Com Content Network
The EMA also initiated an assessment for all COVID‑19 vaccines used in the EU for immune thrombocytopenia (ITP), described as low blood platelet levels that could lead to bruising and bleeding, as a possible side effect, whilst also stating that up to this point no link with any COVID‑19 had been established. [12]
An old filing from Pfizer is being misrepresented. A viral Facebook post claims that Pfizer has recently released a long list of side effects to its COVID-19 vaccine.
A study conducted on 44 rats injected with the Pfizer–BioNTech COVID-19 vaccine at doses over 300 times the human dose by body weight and 44 rats injected with placebo found no statistically significant evidence of any adverse effects on the fertility of female rats or on the health of the offspring of rats (the 3% lower pregnancy rate found ...
In Com-COV2, the first dose is the Oxford–AstraZeneca vaccine or the Pfizer vaccine, and the second dose is the Moderna vaccine, the Novavax vaccine, or a homologous vaccine equal to the first dose, with an interval of 56 or 84 days between doses.
The World Health Organization has classified vaccine related misinformation into five topic areas. These are: threat of disease (vaccine preventable diseases are harmless), trust (questioning the trustworthiness of healthcare authorities who administer vaccines), alternative methods (such as alternative medicine to replace vaccination), effectiveness (vaccines do not work) and safety (vaccines ...
COVID-19 vaccines are safe and effective at protecting people from developing severe illness, being hospitalized, and dying, according to the CDC. This means they can still offer protection even ...
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury ...
It is similar to the approach used by the Oxford–AstraZeneca COVID-19 vaccine and the Russian Sputnik V COVID-19 vaccine [55] [56] which use human embryonic kidney 293 cells for adenovirus vector replication. [57] [58] The Ad26 viral vector lacks the E1 gene required for replication. Therefore, it cannot replicate in the human organism. [59] [60]